Cargando…

Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018

PURPOSE: The study aimed to evaluate meropenem, fosfomycin, berberine hydrochloride, and doxycycline minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae collected from eight provinces in China in 2018. METHODS: The MICs of 540 Neisseria gonorrhoeae isolates (451 isolates selected rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xiao-Li, Xu, Wen-Qi, Liu, Jing-Wei, Zhu, Xiao-Yu, Chen, Shao-Chun, Han, Yan, Dai, Xiu-Qin, Goodman, Isabelle Griffin, Budjan, Christoph, Chen, Xiang-Sheng, Yin, Yue-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751583/
https://www.ncbi.nlm.nih.gov/pubmed/33364794
http://dx.doi.org/10.2147/IDR.S278020
_version_ 1783625694367973376
author Zheng, Xiao-Li
Xu, Wen-Qi
Liu, Jing-Wei
Zhu, Xiao-Yu
Chen, Shao-Chun
Han, Yan
Dai, Xiu-Qin
Goodman, Isabelle Griffin
Budjan, Christoph
Chen, Xiang-Sheng
Yin, Yue-Ping
author_facet Zheng, Xiao-Li
Xu, Wen-Qi
Liu, Jing-Wei
Zhu, Xiao-Yu
Chen, Shao-Chun
Han, Yan
Dai, Xiu-Qin
Goodman, Isabelle Griffin
Budjan, Christoph
Chen, Xiang-Sheng
Yin, Yue-Ping
author_sort Zheng, Xiao-Li
collection PubMed
description PURPOSE: The study aimed to evaluate meropenem, fosfomycin, berberine hydrochloride, and doxycycline minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae collected from eight provinces in China in 2018. METHODS: The MICs of 540 Neisseria gonorrhoeae isolates (451 isolates selected randomly and 89 isolates selected with preference) were determined to meropenem, fosfomycin, berberine hydrochloride, and doxycycline using the agar dilution method, and the MICs of ceftriaxone and azithromycin were detected for comparison. RESULTS: Among 451 randomly selected isolates, the MIC(90) was 0.06 mg/L for meropenem, 64 mg/L for fosfomycin, 64 mg/L for berberine hydrochloride, and 16 mg/L for doxycycline. All isolates showed the MIC ≤ 0.125 mg/L to meropenem, 13 isolates (2.9%) showed MIC > 64 mg/L to fosfomycin, 8 isolates (1.8%) demonstrated MIC > 64 mg/L to berberine hydrochloride, and 271 isolates (60.1%) demonstrated MIC > 1 mg/L to doxycycline. Comparing all 540 tested isolates, a correlation of r = 0.50 (P < 0.001) between meropenem and ceftriaxone MIC was observed. In 24 ceftriaxone-decreased susceptibility isolates, all isolates showed an MIC ≤ 0.125 mg/L for meropenem, 1 isolate (4.2%) showed an MIC > 64 mg/L for fosfomycin, 1 isolate (4.2%) showed an MIC > 64 mg/L for berberine hydrochloride, and 13 isolates (54.2%) showed an MIC > 1 mg/L for doxycycline. In 87 azithromycin resistant isolates, all isolates showed an MIC ≤ 0.125 mg/L for meropenem, 2 isolates (2.3%) showed an MIC > 64 mg/L for fosfomycin, 4 isolates (4.6%) showed an MIC > 64 mg/L for berberine hydrochloride, and 64 isolates (73.6%) showed an MIC > 1 mg/L for doxycycline. CONCLUSION: The in vitro results suggest that meropenem might be a promising treatment option for resistant gonococcal infections, while the effects of fosfomycin and berberine hydrochloride should be further evaluated as potential therapeutic agents. The effectiveness of these drugs in animal experiments and clinical use may need further study.
format Online
Article
Text
id pubmed-7751583
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77515832020-12-22 Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018 Zheng, Xiao-Li Xu, Wen-Qi Liu, Jing-Wei Zhu, Xiao-Yu Chen, Shao-Chun Han, Yan Dai, Xiu-Qin Goodman, Isabelle Griffin Budjan, Christoph Chen, Xiang-Sheng Yin, Yue-Ping Infect Drug Resist Original Research PURPOSE: The study aimed to evaluate meropenem, fosfomycin, berberine hydrochloride, and doxycycline minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae collected from eight provinces in China in 2018. METHODS: The MICs of 540 Neisseria gonorrhoeae isolates (451 isolates selected randomly and 89 isolates selected with preference) were determined to meropenem, fosfomycin, berberine hydrochloride, and doxycycline using the agar dilution method, and the MICs of ceftriaxone and azithromycin were detected for comparison. RESULTS: Among 451 randomly selected isolates, the MIC(90) was 0.06 mg/L for meropenem, 64 mg/L for fosfomycin, 64 mg/L for berberine hydrochloride, and 16 mg/L for doxycycline. All isolates showed the MIC ≤ 0.125 mg/L to meropenem, 13 isolates (2.9%) showed MIC > 64 mg/L to fosfomycin, 8 isolates (1.8%) demonstrated MIC > 64 mg/L to berberine hydrochloride, and 271 isolates (60.1%) demonstrated MIC > 1 mg/L to doxycycline. Comparing all 540 tested isolates, a correlation of r = 0.50 (P < 0.001) between meropenem and ceftriaxone MIC was observed. In 24 ceftriaxone-decreased susceptibility isolates, all isolates showed an MIC ≤ 0.125 mg/L for meropenem, 1 isolate (4.2%) showed an MIC > 64 mg/L for fosfomycin, 1 isolate (4.2%) showed an MIC > 64 mg/L for berberine hydrochloride, and 13 isolates (54.2%) showed an MIC > 1 mg/L for doxycycline. In 87 azithromycin resistant isolates, all isolates showed an MIC ≤ 0.125 mg/L for meropenem, 2 isolates (2.3%) showed an MIC > 64 mg/L for fosfomycin, 4 isolates (4.6%) showed an MIC > 64 mg/L for berberine hydrochloride, and 64 isolates (73.6%) showed an MIC > 1 mg/L for doxycycline. CONCLUSION: The in vitro results suggest that meropenem might be a promising treatment option for resistant gonococcal infections, while the effects of fosfomycin and berberine hydrochloride should be further evaluated as potential therapeutic agents. The effectiveness of these drugs in animal experiments and clinical use may need further study. Dove 2020-12-15 /pmc/articles/PMC7751583/ /pubmed/33364794 http://dx.doi.org/10.2147/IDR.S278020 Text en © 2020 Zheng et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zheng, Xiao-Li
Xu, Wen-Qi
Liu, Jing-Wei
Zhu, Xiao-Yu
Chen, Shao-Chun
Han, Yan
Dai, Xiu-Qin
Goodman, Isabelle Griffin
Budjan, Christoph
Chen, Xiang-Sheng
Yin, Yue-Ping
Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018
title Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018
title_full Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018
title_fullStr Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018
title_full_unstemmed Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018
title_short Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018
title_sort evaluation of drugs with therapeutic potential for susceptibility of neisseria gonorrhoeae isolates from 8 provinces in china from 2018
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751583/
https://www.ncbi.nlm.nih.gov/pubmed/33364794
http://dx.doi.org/10.2147/IDR.S278020
work_keys_str_mv AT zhengxiaoli evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT xuwenqi evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT liujingwei evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT zhuxiaoyu evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT chenshaochun evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT hanyan evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT daixiuqin evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT goodmanisabellegriffin evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT budjanchristoph evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT chenxiangsheng evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018
AT yinyueping evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018